New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:15 EDTBDSIBioDelivery Sciences randomized half the patients required for Clonidine study
BioDelivery Sciences International announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabetic neuropathy. The intent of the study will be to demonstrate the efficacy and safety of Clonidine Topical Gel for the treatment of PDN. An interim analysis of the study, which will be based on the first 50% of patients entering the study, is now anticipated to occur in the Q3 of 2014. It was earlier projected based on estimated patient enrollment the interim analysis would occur in fourth quarter of this year. The purpose of the interim analysis is to confirm the assumptions regarding the study sample size and allow for an increase if needed.
News For BDSI From The Last 14 Days
Check below for free stories on BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
08:52 EDTBDSIBioDelivery Sciences price target raised to $28 from $20 at Summer Street
Summer Street raised its price target for BioDelivery Sciences shares to $28 saying it left the company's analyst day on Friday incrementally more positive. The firm believes its sales estimates for Bunavail and BEMA Buprenorphine may prove to be conservative and reiterates a Buy rating on the stock.
September 3, 2014
05:23 EDTBDSIBioDelivery Sciences to host investor/analyst meeting
Investor/Analyst meeting to be held in New York on September 5 at 12 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use